Teladoc Health Announces Executive Changes and New Board Member

Ticker: TDOC · Form: 8-K · Filed: 2024-09-09T00:00:00.000Z

Sentiment: neutral

Topics: executive-change, board-appointment, compensation

Related Tickers: TDOC

TL;DR

TDOC's CMO is out, new director Yishai Horowitz is in, and exec comp details released.

AI Summary

Teladoc Health, Inc. announced on September 9, 2024, the departure of its Chief Medical Officer, Dr. David M. Schreiner, effective September 6, 2024. The company also announced the appointment of Ms. Yishai Horowitz as a new independent director to its Board of Directors, effective September 9, 2024. Additionally, the company disclosed compensatory arrangements for its executive officers.

Why It Matters

Changes in key executive roles and board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Executive departures and board changes, while common, can introduce uncertainty regarding leadership stability and strategic direction.

Key Players & Entities

FAQ

Who has departed from Teladoc Health, Inc.?

Dr. David M. Schreiner, the Chief Medical Officer, has departed from Teladoc Health, Inc.

When was Dr. David M. Schreiner's departure effective?

Dr. David M. Schreiner's departure was effective September 6, 2024.

Who has been appointed as a new independent director to the Board of Directors?

Ms. Yishai Horowitz has been appointed as a new independent director to the Board of Directors.

When was Ms. Yishai Horowitz's appointment effective?

Ms. Yishai Horowitz's appointment was effective September 9, 2024.

What other information is disclosed in this filing?

The filing also discloses compensatory arrangements for the company's executive officers.

From the Filing

0001477449-24-000200.txt : 20240909 0001477449-24-000200.hdr.sgml : 20240909 20240909160516 ACCESSION NUMBER: 0001477449-24-000200 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240909 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240909 DATE AS OF CHANGE: 20240909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 241287268 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20240909.htm 8-K tdoc-20240909 FALSE 0001477449 0001477449 2024-06-28 2024-06-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification No.) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 9, 2024, Joseph Catapano joined Teladoc Health, Inc. (the “Company”) as its Senior Vice President and Chief Accounting Officer. Mr. Catapano, age 56, previously served as Vice President, Chief Accounting Officer of Pitney Bowes Inc. from August 2017 to September 2024. In this role, he served as the Company’s principal accounting officer. He

View on Read The Filing